| Thomas W. Beetham |
Thomas W. Beetham founded Kiniksa Pharmaceuticals Ltd. Mr. Beetham is Secretary & Chief Legal Officer for Magenta Therapeutics, Inc.
In the past Mr. Beetham was Secretary, Chief Legal Officer & EVP-Operations at Kiniksa Pharmaceuticals Ltd., General Legal Counsel at New England Biolabs, Inc., Corporate Attorney at Genzyme Corp., Attorney at Palmer & Dodge LLP and Chief Legal Officer, Senior VP & General Counsel at Synageva BioPharma Corp.
Thomas W. Beetham received an undergraduate degree from the University of Rochester and a graduate degree and an MBA from Boston College. |
| Alison Francis Lawton |
Alison Francis Lawton is Chairman of Magenta Therapeutics, Inc. She is also on the board of 5 other companies.
In her past career Ms. Lawton occupied the position of Director at Kaleido Biosciences, Inc., Chief Operating Officer at Aura Biosciences, Inc., Chief Operating Officer for X4 Pharmaceuticals, Inc., Senior Vice President of Genzyme Corp. and Senior Vice President & General Manager at Genzyme Biosurgery Corp. (a subsidiary of Genzyme Corp.), Chief Operating Officer at OvaScience, Inc., Principal at Parke-Davis & Co. Ltd., General Manager-Biosurgery at Sanofi, Inc., Head-Genzyme Biosurgery at Sanofi-Aventis, Inc. and Chairman & President at Regulatory Affairs Professionals Society.
Alison Francis Lawton received an undergraduate degree from King's College London. |
| Stephen Frank Mahoney |
Stephen Frank Mahoney founded Kiniksa Pharmaceuticals Ltd. He is President, Chief Financial & Operating Officer at Magenta Therapeutics, Inc. He is also on the board of Vesselon, Inc.
Mr. Mahoney previously was President & Chief Operating Officer for Kiniksa Pharmaceuticals Ltd., Attorney at Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC, Regional Legal Director at Genzyme Corp. and Chief Commercial Officer & Senior Vice President at Synageva BioPharma Corp.
Mr. Mahoney received an undergraduate degree from The Colorado College, a graduate degree from Boston College Law School and an MBA from Wallace E Carroll School of Management. |
| Alexis A. Borisy |
Founder of 9 different companies, including: Foundation Medicine, Inc., Blueprint Medicines Corp. and Relay Therapeutics, Inc. Alexis A. Borisy is an entrepreneur and businessperson who has been the head of 13 different companies and occupies the position of Chairman for Relay Therapeutics, Inc. (which he founded in 2015), Chairman of Tango Therapeutics, Inc., Executive Chairman at EQRx, Inc. (which he founded in 2019), Executive Chairman at EQRx International, Inc. (which he founded in 2020) (a subsidiary of EQRx, Inc.) and Partner at Third Rock Ventures LLC. Alexis A. Borisy is also Co-Chairman at Museum of Science and on the board of 5 other companies.
In the past he held the position of Director at National Venture Capital Association, Chairman for FORMA Therapeutics, Inc. (he founded the company in 2007), Independent Director at Foundation Medicine, Inc. (he founded the company in 2009), Executive Chairman for Warp Drive Bio, Inc., Director at Tango Therapeutics Sub, Inc. and President, Chief Executive Officer & Director at CombinatoRx, Inc. (he founded the company in 2000).
He received an undergraduate degree from The University of Chicago and a graduate degree from Harvard University. |
| Thomas O. Daniel |
Currently, Thomas O. Daniel occupies the position of Chairman for Locanabio, Inc. Dr. Daniel is also Chairman-Overseers Board at The Scripps Research Institute and on the board of 8 other companies.
In his past career Dr. Daniel was Vice President-Research at Amgen, Inc. and Senior Vice President-Discovery Research at Immunex Corp. (a subsidiary of Amgen, Inc.), Venture Partner at ARCH Venture Partners LLC, Chairman-Research Division at Celgene Corp., Chief Scientific Officer & Director at Ambrx, Inc. and Professor at Vanderbilt University.
Dr. Daniel received a doctorate from The University of Texas Southwestern Medical Center, an undergraduate degree from Southern Methodist University and a doctorate from The University of Texas at Austin. |
| Bruce Lee Booth |
Founder of 5 different companies, among them: Kymera Therapeutics, Inc., Viridian Therapeutics, Inc. and Rodin Therapeutics, Inc. Bruce Lee Booth is an entrepreneur and businessperson who has been at the head of 13 different companies and currently occupies the position of Chairman at Nimbus Therapeutics LLC (which he founded in 2011), Chairman of Avrobio, Inc., Chairman for Kymera Therapeutics, Inc. (which he founded in 2015), Chairman for HotSpot Therapeutics, Inc., Chairman at Arkuda Therapeutics, Inc., Chairman for Vigil Neuroscience, Inc., Chairman at Matchpoint Therapeutics, Inc., Partner at Atlas Ventures Advisors, Inc., Partner at Atlas Venture Life Science Advisors LLC and Director at Sionna Therapeutics, Inc. Dr. Booth is also Member of Council on Foreign Relations, Inc. and on the board of 8 other companies.
In the past Bruce Lee Booth held the position of Chairman of Cogent Biosciences, Inc., Chairman at On-Q-ity, Inc., Chairman for Quartet Medicine, Inc., Chairman at Viridian Therapeutics, Inc. (he founded the company in 2006) and Chairman of miRagen Therapeutics, Inc. (a subsidiary of Viridian Therapeutics, Inc.), Associate Principal at McKinsey & Co., Inc., Principal at Caxton Health Holdings LLC, Chairman of Rodin Therapeutics, Inc. (he founded the company in 2013), Director at Proprius Pharmaceuticals, Inc., Director at Stromedix, Inc. and Director at Prestwick Services LLC.
Bruce Lee Booth received a doctorate from the University of Oxford and an undergraduate degree from The Pennsylvania State University. |
| Anne Mcphaul McGeorge |
Presently, Anne Mcphaul McGeorge is Advisor at Clayton Associates Holdings LLC. Ms. McGeorge is also Chairman of Be The Match Foundation, Member of The American Institute of Certified Public Accountants, Member of American College of Healthcare Executives, Member of American Health Lawyers Association, Member of Healthcare Financial Managers Association, Member of Women Business Leaders of the US Health Care Industry Fnd and Professor at the University of North Carolina at Chapel Hill and on the board of 6 other companies.
She previously occupied the position of Senior Tax Manager at KPMG LLP, Partner at Deloitte & Touche LLP, Managing Partner-Health Care Industry Practice at Grant Thornton LLP and Partner at Arthur Andersen LLP.
Anne Mcphaul McGeorge received an undergraduate degree from The College of William & Mary and a graduate degree from the University of Virginia. |
| David T. Scadden |
Founder of 7 different companies, including: Fate Therapeutics, Inc., Magenta Therapeutics, Inc. and Massachusetts General Hospital Cancer Center, David T. Scadden is an entrepreneur is Chairman-Emeritus & Professor at Harvard University, Director-Regenerative Medicine Center at The General Hospital Corp. (he founded the company), Associate Member at Massachusetts Institute of Technology, Member of American Academy of Arts & Sciences, Member of National Academy of Medicine (United States), Associate Member at The Broad Institute, Inc., Fellow at American Association, Chairman-Emeritus & Professor at Harvard Medical School and Fellow at American College of Physicians and on the board of 7 other companies.
He previously held the position of Director-Hematologic Malignancies Center at Massachusetts General Hospital Cancer Center (he founded the company in 2003), Member-External Experts Board at National Heart, Lung & Blood Institute and Member-Scientific Counselors Board at National Cancer Institute.
David T. Scadden received an undergraduate degree from Bucknell University, a graduate degree from Case Western Reserve University and a doctorate from the University of Lund. |
| Amy L. Ronneberg |
Currently, Amy L. Ronneberg is Chief Executive Officer, CFO & Chief of Staff at Be The Match, Chief Financial Officer & Chief Operating Officer at North American Membership Group, Inc., President & Chief Executive Officer of Be The Match Biotherapies and Chief Financial Officer at National Marrow Donor Program. Amy L. Ronneberg is also on the board of Allina Health System, Inc., Medical Alley Association and Magenta Therapeutics, Inc.
Ms. Ronneberg previously was Executive VP, Chief Financial & Operating Officer at Scout Media Holdings, Inc., VP-Learner Services & Operations at Capella Education Co., Chairman for Twin Cities In Motion and Vice President-Finance & Operations at Capella University LLC.
Amy L. Ronneberg received an undergraduate degree from the University of Wisconsin-Eau Claire and an MBA from Capella University LLC. |
| Jeffrey W. Albers |
Jeffrey W. Albers holds the position of Executive Chairman at Blueprint Medicines Corp., Independent Chairman of MOMA Therapeutics, Inc., Chairman of Pheon Therapeutics Ltd. and Venture Partner at Atlas Ventures Advisors, Inc. He is also on the board of Magenta Therapeutics, Inc. and Kymera Therapeutics, Inc. and Director-New England Division at American Cancer Society, Inc.
In his past career Jeffrey W. Albers occupied the position of VP-US Hematology & Oncology Business Unit at Genzyme Corp., Vice President-US Hematology & Oncology Business at Sanofi, Attorney at Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC and President of Algeta ASA.
Jeffrey W. Albers received an undergraduate degree from Indiana University and a graduate degree and an MBA from Georgetown University. |
| Michael J. Vasconcelles |
Currently, Michael J. Vasconcelles occupies the position of Chief Medical Officer for ImmunoGen, Inc. and Senior Advisor at Frazier Management LLC. Dr. Vasconcelles is also on the board of Molecular Partners AG, Magenta Therapeutics, Inc. and Molecular Partners, Inc. and Member of American Society of Clinical Oncology and Member of American Society of Hematology.
In his past career he occupied the position of Chief Medical Officer for Cogent Biosciences, Inc., Head-Personalized Medicine & Companion Diagnostics at Sanofi Oncology, Group VP & Head-Global Therapeutic Area at Genzyme Corp., Global Therapeutic Area Head-Transplant & Oncology at Sanofi SA, Senior VP & Head-Oncology Therapy Area Unit at Takeda Pharmaceuticals International, Inc. and Chief Medical Officer at Flatiron Health, Inc.
He received an undergraduate degree from Northwestern University and a doctorate from Feinberg School of Medicine. |
